SciELO - Scientific Electronic Library Online

 
vol.99 número8Resultados del drenaje de la vía biliar por CPRE en pacientes con edad geriátricaEl modelo de la dimetilhidrazina no sirve para evaluar el efecto del etanol sobre el cáncer colorrectal índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Española de Enfermedades Digestivas

versión impresa ISSN 1130-0108

Resumen

MOLINA INFANTE, J.; PEREZ GALLARDO, B.  y  FERNANDEZ BERMEJO, M.. Update on medical therapy for obscure gastrointestinal hemorrhage. Rev. esp. enferm. dig. [online]. 2007, vol.99, n.8, pp.457-462. ISSN 1130-0108.

The development of capsule endoscopy and double-balloon enteroscopy has increased diagnostic and therapeutic rates in obscure gastrointestinal hemorrhage, where angiodysplasia of the small bowel is the most frequent cause. Nevertheless, almost 25-40% of patients who are not candidates or do not respond to endoscopic, angiographic, or surgical management may be at high risk of rebleeding, and therefore lack a clearly effective medical therapy. The utility of hormonal therapy remains unclear and is burdened by adverse effects. Subcutaneous octreotide usually controls bleeding but does not seem adequate for mainteinance therapy. Non-selective beta-blockers alone or in combination with other treatments, as in the prophylaxis of portal hypertension variceal bleeding, may be helpful. Recently, octreotide LAR, a depot formulation administered once a month intramuscularly, and oral thalidomide, a powerful inhibitor of angiogenesis, have demonstrated their effectiveness and safety for long-term therapy in anecdotal case reports and deserve further investigation.

Palabras clave : Obscure gastrointestinal haemorrhage; Angiodysplasia; Hormonal therapy; Octreotide; Octreotide LAR; Thalidomide; Beta-blockers; Medical therapy.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons